Compounds > nsc 710305
Page last updated: 2024-12-08

nsc 710305

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Phortress: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9804228
CHEMBL ID1793884
MeSH IDM0414710

Synonyms (18)

Synonym
nsc-710305
phortress
CHEMBL1793884
nsc 710305
328087-38-3
(2s)-2,6-diamino-n-[4-(5-fluoro-2-benzothiazolyl)-2-methylphenyl]hexanamide dihydrochloride
AKOS024458457
gs-1302 ,
5f-df-203-l-lysinamide dihydrochloride
(2s)-2,6-diamino-n-(4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methyl-phenyl)hexanamide hydrochloride
AXR52N9SMF ,
hexanamide, 2,6-diamino-n-(4-(5-fluoro-2-benzothiazolyl)-2-methylphenyl)-, hydrochloride (1:2), (2s)-
unii-axr52n9smf
328087-38-3 (hcl)
(s)-2,6-diamino-n-(4-(5-fluorobenzo[d]thiazol-2-yl)-2-methylphenyl)hexanamide dihydrochloride
CS-0025314
(2s)-2,6-diamino-n-[4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylphenyl]hexanamide;dihydrochloride
HY-103223

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"A series of water-soluble L-lysyl- and L-alanyl-amide prodrugs of the lipophilic antitumor 2-(4-aminophenyl)benzothiazoles has been synthesized to address formulation and bioavailability issues related to the desired parenteral administration of the chosen clinical candidate."( Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
Hutchinson, I; Jennings, SA; Stevens, MF; Vishnuvajjala, BR; Westwell, AD, 2002)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID28855The compound was tested for its solubility at a pH of 7.42002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID28852The compound was tested for its solubility at a pH of 10.52002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID28854The compound was tested for its solubility at a pH of 6.32002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID28857The compound was tested for its solubility at a pH of 9.62002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID28856The compound was tested for its solubility at a pH of 8.52002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID28853The compound was tested for its solubility at a pH of 5.02002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazoles
[no description available]		4.24501,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0310taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
nsc 674495
NSC 674495: structure in first source		3.5220
5f-203
2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole: structure in first source		3.8530
sesquiterpenes
[no description available]		2.0310
fumagillin
[no description available]		2.0310antibiotic antifungal drug;
carboxylic ester;
dicarboxylic acid monoester;
meroterpenoid;
organooxygen heterocyclic antibiotic;
spiro-epoxide		angiogenesis inhibitor;
antibacterial drug;
antimicrobial agent;
antiprotozoal drug;
fungal metabolite;
methionine aminopeptidase 2 inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0510
Breast Cancer
[description not available]		02.0210
Experimental Neoplasms
[description not available]		02.0210
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0210
Colorectal Cancer
[description not available]		02.0310
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0310